Heyholder
‹ Activism Filings

ILYANG PHARMACEUTICAL CO.,LTD Q3 operating profit KRW 5.2 billion, turning profitable; revenue KRW 80.3 billion

ILYANG PHARMACEUTICAL CO.,LTD· Periodic Report

AI summary · Not investment advice

Ilyang Pharmaceutical sold KRW 80.3 billion worth in Q3 and earned KRW 5.2 billion from its main business, turning profitable from a loss a year earlier and from the previous quarter.

Operating profit · 3 months

KRW 5.2 billion

Key facts

Revenue (3 months)
KRW 80.3 billion
Net income (3 months)
KRW 3.4 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 68.8 billion
Revenue (year to date)
KRW 210.5 billion
Operating profit (prior-year 3 months)
KRW -157.7 million
Operating profit (year to date)
KRW -8.9 billion
Net income (prior-year 3 months)
KRW 8.4 billion
Net income (year to date)
KRW 18.0 billion

Commentary

AI commentary · Not investment advice

What happened

Ilyang Pharmaceutical reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 80.30 billion. That is 16.7% higher than the same 3 months a year earlier, which had KRW 68.83 billion. It is also 23.3% higher than the previous quarter. Sales for the year so far are KRW 210.51 billion.

In the company's terms

Operating profit (profit from its main business) for the latest 3 months was KRW 5.23 billion. A year earlier, the same 3 months had an operating loss of KRW 0.16 billion, so it turned to a profit. It also turned to a profit from the previous quarter. For the year so far, operating profit is still a loss of KRW 8.91 billion.

What changes for shareholders

Net income (final profit after taxes and other costs) for the latest 3 months was KRW 3.39 billion. That is 59.6% lower than the KRW 8.38 billion of a year earlier. It turned to a profit from the previous quarter. Net income for the year so far is KRW 18.01 billion.

Comments

No comments yet

Comments from shareholders will appear here.